Clinical Efficacy of Sildenafil in Treatment of Pulmonary Arterial Hypertension in Dogs
Authors:
- 1 July 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 24 (4) , 850-854
Abstract
Background: Pulmonary arterial hypertension (PAH) in dogs carries a poor prognosis. Sildenafil increases exercise capacity and improves hemodynamics in people with PAH. Hypothesis/Objectives: Dogs receiving sildenafil will have lower pulmonary arterial pressure, increased exercise capacity, and better quality of life (QOL) than dogs receiving placebo. Animals: Thirteen dogs with echocardiographic evidence of PAH. Methods: Prospective short-term, randomized, placebo controlled, double-blind, crossover study. Dogs with PAH were randomly allocated to receive sildenafil or placebo for 4 weeks, followed by the alternative treatment for 4 weeks. Results: Dogs receiving sildenafil had a significantly lower estimated pulmonary arterial pressure (median, 56 mmHg; range, 34–83 mmHg) than at baseline (median, 72 mmHg; range, 61–86 mmHg; P= .018), but not significantly lower than those receiving placebo (median, 62 mmHg; range, 49–197 mmHg). Exercise capacity was significantly greater in dogs receiving sildenafil than those receiving placebo (mean activity count per minute: 101 ± 47 versus 74 ± 32; P= .05). QOL scores were significantly higher in dogs receiving sildenafil than dogs receiving placebo. Conclusions and Clinical Importance: Sildenafil decreases systolic pulmonary arterial pressure from baseline in dogs with PAH and is associated with increased exercise capacity and QOL when compared to treatment with placebo.Keywords
This publication has 21 references indexed in Scilit:
- Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary HypertensionChest, 2008
- Sildenafil Improves Health-Related Quality of Life in Patients With Pulmonary Arterial Hypertension*Chest, 2008
- Retrospective Evaluation of Sildenafil Citrate as a Therapy for Pulmonary Hypertension in DogsJournal of Veterinary Internal Medicine, 2006
- Sildenafil Citrate Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2005
- Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophyNature Medicine, 2005
- Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertensionJACC, 2004
- Clinical efficacy of sildenafil in primary pulmonary hypertensionJACC, 2004
- Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial HypertensionCirculation, 2002
- Primary Pulmonary HypertensionNew England Journal of Medicine, 1997
- Survival in Patients with Primary Pulmonary HypertensionAnnals of Internal Medicine, 1991